Clinical Trials Logo

Clinical Trial Details — Status: Recruiting

Administrative data

NCT number NCT06161922
Other study ID # ML44677
Secondary ID
Status Recruiting
Phase
First received
Last updated
Start date October 26, 2023
Est. completion date April 2025

Study information

Verified date November 2023
Source Fudan University
Contact Keda Yu, MD, PhD
Phone +8618017317597
Email yukeda@fudan.edu.cn
Is FDA regulated No
Health authority
Study type Observational

Clinical Trial Summary

This is a non-interventional observational, multi-center cohort study to evaluate patient-reported outcomes in Chinese HER2+ early breast cancer patients undergoing (neo) adjuvant anti-HER2 based therapy and describe changes over time, from baseline to 12 months.


Description:

This is a non-interventional observational, multi-center cohort study with primary prospective data collection. This study will be conducted at approximately 10 sites in China. The study population is Chinese HER2+ early breast cancer patients receiving (neo) adjuvant anti-HER2 based therapy. Patients who are eligible for (neo) adjuvant anti-HER2 based therapy will enroll in this study. Treatment choice in this non-interventional study will be at the discretion of the treating physician as per CACA-CBCS guidelines. Participants are longitudinally assessed at baseline (T0, before treatment), during chemotherapy (T1, after 2 cycles), 1-month after completion of chemotherapy (T2) and at 12-month follow-up (T3). The PRO instruments will be captured by electronic devices through WeChat mini-program which are input by patients, before or after their clinic visit but before administration of anti-HER2 therapy. Paper questionnaires will be available only as a last option if the electronic devices cannot be used for any reason (such as issues with internet access or if the device is not working). Oncology staff provided no assistance with filling in the questionnaires, but a prerecorded video will provide a detailed explanation of the questionnaires before the ePRO questionnaires. The PROs data will be restored centrally at the server of the leading site. The usage of PROs is considered non-interventional according to local regulation. PRO measures include EORTC QLQ-C30, PDQ-5 (cognitive), PHQ-9 (depression), GAD-7 (anxiety) and Insomnia Severity Index (ISI). Patient satisfaction for subcutaneous injection will be assessed using TASQ-SC at T3.


Recruitment information / eligibility

Status Recruiting
Enrollment 600
Est. completion date April 2025
Est. primary completion date April 2025
Accepts healthy volunteers No
Gender Female
Age group 18 Years and older
Eligibility Inclusion Criteria: 1. Patients aged =18 years; 2. Women; 3. Have signed the informed consent form as per local regulations; 4. Newly diagnosed with non-metastatic breast cancer (stage I-II-III, HER2+) at the time of starting anti-HER2 therapy; 5. Be able to comply with the follow-up visits, assessments, answering questionnaires. Exclusion Criteria: 1. Metastatic breast cancer; 2. Prior systemic treatment for any malignancy; 3. Active secondary cancer requiring anti-HER2 therapy; 4. Vulnerable populations [e.g., decisional impaired (cognitive, psychiatric), terminally ill, prisoners], or patients who, in the opinion of the investigator have a condition that precludes their ability to provide an informed consent; 5. Men.

Study Design


Related Conditions & MeSH terms


Locations

Country Name City State
China Keda Yu Shanghai

Sponsors (1)

Lead Sponsor Collaborator
Fudan University

Country where clinical trial is conducted

China, 

Outcome

Type Measure Description Time frame Safety issue
Other Demographics characteristics Demographics characteristics: include age, height in meters, weight in kilograms, and WHO Performance Status score.
The age of the patients will be measured in years, height will be documented by meters, weight by kilograms, and WHO Performance Status score will be classified into 0-4 levels.
0: able to carry out all normal activity without restriction.
restricted in strenuous activity but ambulatory and able to carry out light work.
ambulatory and capable of all self-care but unable to carry out any work activities; up and about more than 50% of waking hours.
symptomatic and in a chair or in bed for greater than 50% of the day but not bedridden.
completely disabled; cannot carry out any self-care; totally confined to bed or chair.
Through study completion, an average of 1 year.
Other Socio-economic status Socio-economic status: include income, education, and marital status. Through study completion, an average of 1 year.
Other Clinical characteristics Clinical characteristics: include assessment of the primary site, histology, TNM stage, histological grade, ER/PR status, which will obtained from the pathology results.
The primary site will be documented by surgeons and pathologists, histology will be decided by pathologists, TNM stage will be recorded according to the pathology results, histological grade will be documented by WHO grade I to III, ER/PR status will be measured with immumohistochemical staining.
Through study completion, an average of 1 year.
Other Treatment sequence (neoadjuvant vs adjuvant) checklist Patients receiving neoadjuvant or adjuvant treatments in fact. Through study completion, an average of 1 year.
Other Clinical treatment checklist Clinical treatment: include breast surgery (Mastectomy vs Conservative surgery), axillary surgery (axillary dissection vs sentinel node biopsy), radiation therapy, anti-HER2 therapy (pertuzumab vs. pyrotinib), chemotherapy (yes vs. no) Through study completion, an average of 1 year.
Primary EORTC QLQ-C30 score EORTC QLQ C30 /+ BR23(EORTC breast cancer-specific quality of life) questionnaire to evaluate quality of life.
Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 1 score, "a little" for 2 score, "quit a bit" for 3 score and "very much" for 4 score. A higher score indicated a worse quality of life.
Through study completion, an average of 1 year.
Secondary PDQ-5 score Perceived Deficits Questionnaire to capture decline in cognitive function. Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including " never" for 0 score, "rarely" for 1 score, " sometimes" for 2 score and " often" for 3 score, "almost always"for 4 score. A higher score indicated a more serious decline in cognitive function. Through study completion, an average of 1 year.
Secondary PHQ-9 score Patient Health Questionnaire to measure the severity of depression. Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 0 score," several days " for 1 score, " more than half the days " for 2 score and " nearly every day " for 3 score. A higher score indicated a worse state. Through study completion, an average of 1 year.
Secondary GAD-7 score GAD-7 (Generalized Anxiety Disorder-7) questionnaire to evaluate anxiety: includes scores for all 7 items and date of self-assessment at T0 to T3.
Participants report the extent to which they have experienced those symptoms or problems during the past week. Each of the symptoms or problems is indicated with four extents, including "not at all" for 0 score," several days " for 1 score, " more than h
Through study completion, an average of 1 year.
Secondary ISI score ISI (Insomnia Severity Index) questionnaire to evaluate Insomnia Severity: includes scores for all 7 items and date of self-assessment .
Participants report the extent to which they have experienced those symptoms or problems during the past two weeks. Each of the symptoms or problems is indicated with four extents, the total value range from 0 to 21, and higher scores mean a more severe insomnia.
Through study completion, an average of 1 year.
Secondary TASQ-SC score Therapy Administration Satisfaction Questionnaire is a 12-item questionnaire measuring the impact of each mode of treatment administration on five domains: physical impact, psychological impact, impact on activities of daily living, convenience, and satisfaction. Each of the domain/scale scores is scored on a 1-100 scale, where 0 is worst and 100 is best. Through study completion, an average of 1 year.
See also
  Status Clinical Trial Phase
Recruiting NCT04095390 - A Phase Ⅱ Trial of Pyrotinib Combination With CDK4/6 Inhibitor SHR6390 in Patients Prior Trastuzumab-treated Advanced HER2-Positive Breast Cancer Phase 2
Recruiting NCT04578106 - Omission of Surgery in Clinically Low-risk HER2positive Breast Cancer With High HER2 Addiction and a Complete Response Following Standard Anti-HER2-based Neoadjuvant Therapy Phase 2
Terminated NCT01912963 - Phase II Study of Eribulin Mesylate, Trastuzumab, and Pertuzumab in Women With Metastatic, Unresectable Locally Advanced, or Locally Recurrent HER2-Positive Breast Cancer Phase 2
Completed NCT01855828 - Phase 2 Trial of Pertuzumab and Trastuzumab With Weekly Paclitaxel and Chemotherapy for HER2 Positive Breast Cancer Phase 2
Terminated NCT01705340 - Akt Inhibitor MK2206, Lapatinib Ditosylate, and Trastuzumab in Treating Patients With Locally Advanced or Metastatic HER2-Positive Breast , Gastric, or Gastroesophageal Cancer That Cannot Be Removed By Surgery Phase 1
Recruiting NCT04094896 - TCHP Versus EC -THP as Neoadjuvant Treatment for HER2-Positive Breast Cancer Phase 2
Recruiting NCT06087120 - Investigate the Prognostic and Predictive Value of ctDNA During Neoadjuvant Chemotherapy for Breast Cancer.
Recruiting NCT05346861 - Pyrotinib Rechallenge in Her2-positive Metastatic Breast Cancer Pretreated With Pyrotinib and Trastuzumab Phase 3
Recruiting NCT04899908 - Stereotactic Brain-directed Radiation With or Without Aguix Gadolinium-Based Nanoparticles in Brain Metastases Phase 2
Completed NCT03330561 - PRS-343 in HER2-Positive Solid Tumors Phase 1
Recruiting NCT04997798 - Dalpiciclib in Combination With Exemestane and Trastuzumab Plus Pyrotinib in Early Triple Positive Breast Cancer Phase 2
Not yet recruiting NCT04034823 - KN035 in Combination With Trastuzumab and Docetaxel in HER2-positive Breast Cancer Phase 2
Completed NCT04756921 - 18F-FDG Uptake Heterogeneity Predicts Pyrotinib Response
Completed NCT03140553 - TCH Versus EC-TH as Neoadjuvant Treatment for HER2-Positive Breast Cancer Phase 2
Completed NCT03094052 - Incidence and Severity of Diarrhea in Patients With HER2 Positive Breast Cancer Treated With Trastuzumab and Neratinib Phase 2
Recruiting NCT05511844 - Study of ORM-5029 in Subjects With HER2-Expressing Advanced Solid Tumors Phase 1
Recruiting NCT05325632 - Study of HER2 Directed Dendritic Cell (DC1) Vaccine + Weekly Paclitaxel, Trastuzumab & Pertuzumab Phase 2
Recruiting NCT05710666 - Neoadjuvant Trastuzumab Deruxtecan (T-DXd) With Response-directed Definitive Therapy in Early Stage HER2-positive Breast Cancer (SHAMROCK Study) Phase 2
Not yet recruiting NCT05063643 - Cardiotoxicity of Targeted Therapy for HER-2 Positive Breast Cancer Patients at High Altitude
Not yet recruiting NCT03684863 - Capecitabine in HER-2 Positive Breast Cancer With Pathologic Residual Tumors After Preoperative Chemotherapy Phase 2